Introduction
Protective immunity against pathogens relies on the production of high-affinity antibodies by long-lived plasma cells (PCs). Moreover, the ability to respond faster and with more potent antibodies to subsequent encounters with the same infectious agent depends on the generation of long-lived memory B cells. Both, high-affinity memory B cells and PCs differentiate from antigenspecific B cells that are recruited into the GC reaction during T cell-dependent immune responses (1) . In GCs, B cells undergo clonal expansion, a process during which they accumulate mutations at high frequency within the Ig heavy and light chain variable (V) region genes. The highly dynamic nature of the GC reaction is characterized by repeated cycles of cell division, Ig somatic mutation, and strict selection based on the ability of B cells to capture and present antigen to T follicular helper cells (2) . These processes occur within distinct areas of the GC reached by B cells through migratory paths regulated by chemokine gradients (1) . The molecular determinants enabling cyclic reentry of B cells into the proliferating and mutating compartment of centroblasts, preventing terminal differentiation and the ensuing exit from the GC, remain poorly characterized.
Polycomb group (PcG) proteins act within 2 main polycomb repressive complexes (PRC1 and PRC2) to promote gene silencing. PRC1 and PRC2 catalyze posttranslational modifications of specific lysine residues in core histone tails, resulting in chromatin compaction (3) . Changes in chromatin conformation regulated by PcG activity represent important molecular switches that control cell differentiation, proliferation, and survival in prenatal and postnatal life (4) . Enhancer of zeste homolog 2 (EZH2) is the main catalytic subunit of PRC2. Through its SET domain, EZH2 catalyzes histone H3 lysine 27 trimethylation (H3K27me3), which is enriched at transcription start sites (TSSs) of repressed genes (5) . Together with H3K4me3, H3K27me3 is found at promoters of regulators of lineage specification, where it acts to fine-tune their expression (6) .
EZH2 is expressed at high levels in human GC B cells (7, 8) . Moreover, whole-exome sequencing efforts have revealed that EZH2 gain-of-function mutations are among the most common genetic alterations identified in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma originating from GC B cells (9, 10) . Together, these results point to a critical role of EZH2 in GC B cell function and in the pathogenesis of GC-derived nonHodgkin lymphoma (NHL).
Using GC B cell-specific gene targeting in mice, we show that EZH2 methyltransferase activity is required to protect GC B cells against genotoxic damage induced by activation-induced cytidine deaminase (AID). Moreover, we found that EZH2 is necessary to repress B-lymphocyte-induced maturation protein 1 (Blimp1) and Irf4 expression in GC B cells to limit terminal B cell differentiation induced by IL-21. Through these mechanisms, EZH2 ensures the persistence of B cells in the GC reaction, thus allowing the generation of high-affinity antibodies and memory B cells. We also found that constitutively active EZH2 is critical to stably repress tumor suppressor BLIMP1 expression in GC-type DLBCL cells, thereby possibly contributing to lymphomagenesis.
Results

Ezh2 is upregulated in mouse GC B cells.
To investigate the expression of Ezh2 in mouse mature B cell subsets, we performed quantitative RT-PCR (qRT-PCR) analysis. Low Ezh2 mRNA levels were detected in follicular, marginal zone, and B-1 mature B cell subsets. A substantial increase in both Ezh2 transcript ( Figure 1A ) and protein ( Figure 1B ) levels was detected in B cells upon recruitment into the GC reaction during a T cell-dependent immune response. Within the GC, EZH2 was expressed predominantly in proliferating CXCR4 + centroblasts (Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/ JCI70626DS1). The differentiation of GC B cells into long-lived IgG1 + memory B cells or PCs coincided with lower, yet detectable, Ezh2 transcripts ( Figure 1A ). These results pointed to a role of EZH2 in GC B cell physiology.
Reduced number of GC B cells upon inducible Ezh2 inactivation.
To study the specific role of EZH2 in GC B cells, conditional Ezh2 knockout (Ezh2 fl ) mice carrying loxP sites flanking exons coding for the catalytic SET domain (11) were crossed with C 1-cre knockin animals expressing Cre recombinase upon onset of Ig class switch recombination (CSR) (12) . Ezh2 fl mice were also crossed with Cr2-cre transgenic mice to inactivate Ezh2 in all peripheral mature B cells (13) . Ezh2 fl/fl :C 1-cre conditional mutants and Ezh2 fl/+ :C 1-cre controls (hereafter referred to as controls) were immunized with alum-precipitated 4-hydroxy-3-nitrophenyl acetyl (NP) conjugated to chicken globulin (CGG) to induce GC responses. Flow cytometry analysis revealed an average 3-fold reduction in percentages and absolute numbers of splenic CD19 + CD38 lo CD95 hi GC B cells in Ezh2 fl/fl : C 1-cre animals, 12 to 14 days after immunization, at the peak of the response (Figure 1 , C and D, and Supplemental Figure 1B ). Histological analysis of spleen sections of immunized mice revealed a significant reduction in peanut agglutinin (PNA)-positive GCs in Ezh2 mutant animals ( Figure 1E and Supplemental Figure 1C ). Similar results were observed analyzing GC responses in Ezh2 fl/fl :Cr2-cre mutants (Supplemental Figure 1D ) that showed normal distribution and number of peripheral B cell subsets (Supplemental Figure 1 , E and F).
To reveal the identity of the remaining GC B cells in Ezh2 fl/fl : C 1-cre animals, we determined the status of the Ezh2 fl gene by quantitative PCR (qPCR) analysis. Whereas Cre-mediated recombination occurred in the majority of GC B cells in control animals, GC B cells of Ezh2 fl/fl :C 1-cre mutants retained substantial levels of the unrecombined Ezh2 fl allele ( Figure 1F ), giving rise to full-length Ezh2 transcripts (Supplemental Figure  1G) . The counter selection of Ezh2 mutant GC B cells was confirmed in Ezh2 fl/fl :Cr2-cre mice (Supplemental Figure 1H ) and in animals generated from crosses of Ezh2 fl :C 1-cre mice to the R26-yfp Cre reporter strain. Flow cytometry analysis of splenic B cells isolated from immunized mice revealed a 4-to 6-fold reduction in the Figure 1I ), indicating that inactivation of the PcG protein had occurred within the GC. These studies reveal that EZH2 is strictly required for the persistence of B cells within the GC reaction.
Poor antibody responses and fewer memory B cells upon GC B cellspecific inactivation of Ezh2. We next investigated the effects of GC B cell-specific inactivation of Ezh2 on the ability of animals to mount an antigen-specific T cell-dependent antibody response. For this purpose, Ezh2 fl/fl :C 1-cre mutants and controls were immunized with NP-CGG. On average, NP-specific IgG1 titers were over 10-fold reduced in Ezh2 mutant mice throughout the primary immune response (Figure 2A ). The percentage of high-affinity NPspecific IgG1 + memory B cells was also significantly reduced in the spleens of Ezh2 fl/fl :C 1-cre animals 2 months after primary immunization ( Figure 2B and Supplemental Figure 2A ). The reduction was already detected at the peak of the primary GC response, indicating that EZH2 is necessary for the formation of IgG1 memory B cells (Supplemental Figure 2B) .
To study the role of EZH2 in antibody affinity maturation, GC B cells from the spleens of NP-CGG-immunized Ezh2 fl/fl :C 1-cre: R26-yfp mice were sorted on the basis of YFP expression to enrich for Ezh2 mutants. Mutation analysis of the V H 186.2 gene expressed by NP-specific B cells revealed a substantial reduction in the overall mutation frequency in Ezh2 mutant GC B cells (Table 1) . Moreover, the frequency of replacement mutations, causing a tryptophan-to-leucine substitution at codon 33 that confers a 10-fold higher affinity for NP to the BCR, was reduced in mutant GC B cells (Table 1 ). In accordance with these results, Ezh2 fl/fl :C 1-cre mice showed a reduction in high-affinity NP-specific IgG1 serum titers in primary and recall immune responses ( Figure 2C ). To assess whether the reduction in IgG1 titers was due to a intrinsic defect in Ig CSR, primary B cells from Ezh2 fl/fl :Cr2-cre mice were stimulated in vitro with LPS and IL-4. Flow cytometry analysis revealed a sizeable fraction of IgG1 + B cells in Ezh2 mutant cultures ( Figure 2D ), thus excluding major defects in Ig CSR. The inactivation of Ezh2 in B cells was confirmed by expression of a truncated, catalytic-inert (EZH2 SET ) form of the protein and by a reduction in global H3K27me3 levels (Supplemental Figure 2C) . In agreement with the established role of EZH2 in the repression of the Cdkn2a tumor suppressor locus (14) , Cdkn2a transcripts increased over 9 fold in Ezh2 mutant GC B cells ( Figure 3C ). To test whether the proapoptotic factor p19 ARF , encoded by Cdkn2a, was responsible for the death of Ezh2 mutant GC B cells, we analyzed Ezh2Cdkn2a double-mutant mice (Ezh2 fl/fl :Cdkn2a -/-:C 1-cre mice). Flow cytometry analysis of NP-CGG-immunized mutants and controls (Ezh2 fl/+ :Cdkn2a -/-:C 1-cre mice) revealed a significant reduction in the percentage of double-mutant GC B cells compared with that in controls ( Figure 3D ), which was associated with an increased percentage of apoptotic cells ( Figure 3E ). Moreover, genomic qPCR analysis indicated the persisting counter selection of GC B cells carrying Ezh2 recombined alleles in compound mutants ( Figure 3F ). Next, we attempted to rescue apoptosis of Ezh2 mutant GC B cells through enforced expression of the antiapoptotic protein BCL2, using the E BCL2 transgene (15) . Flow cytometry analysis and quantitative assessment of the Ezh2 fl allele revealed lower frequency of GC B cells, increased percentage of apoptotic cells, and counter selection of Ezh2 mutant GC B cells in compound mutants (Supplemental Figure 3 , B-D). In conclusion, EZH2 sustains GC B cell survival independently of its repression of p19 ARF and without limiting mitochondrial apoptosis.
Ezh2 protects GC B cells against AID-dependent genotoxic damage. Both in vitro and in vivo studies have provided evidence that PcG proteins, including EZH2, can participate in DNA damage responses (16) (17) (18) (19) . We thus investigated whether EZH2 protected Cr2-cre) mice were stimulated in vitro with LPS and, shortly after, were exposed to a single dose of 0.1 and 1 Gy of IR, respectively. The fraction of apoptotic B cells was determined 24 hours after irradiation by TUNEL staining. Whereas the majority of B cells succumbed to 1 Gy of IR (irrespective of Ezh2 genotype), the treatment with 0.1 Gy caused minor toxicity to Ezh2 proficient B cells. In contrast, the cultures of Ezh2 mutant B cells exposed to the same sublethal IR dose consisted of mostly TUNEL + cells (Figure 4A ). In accordance with this result, we found a significantly higher number of DNA damage response foci marked by 53BP1 in Ezh2 mutant B cells after exposure to IR ( Figure 4B ). Since AID is a major determinant of genotoxic stress in GC B cells (20), we tested whether EZH2 inhibition increased the sensitivity of B cells to AID toxicity. Initially, we compared the behavior of Ezh2 mutant B cells after in vitro stimulation with either LPS/IL-4 or an antibody activating the Toll-like receptor homolog RP-105, as they differ in the ability to induce AID (Supplemental Figure 4A) . Ezh2 mutant B cells responded to both mitogenic stimuli (Supplemental Figure 4B ). However, only LPS/IL-4 stimulation, which induced robust AID expression, caused a significant increase in apoptosis of Ezh2 mutant B cells and lower numbers of viable cells after 4 days of in vitro culture ( Figure 4C and Supplemental Figure 4C ). This effect was particularly evident among IgG1 class-switched B cells (Supplemental Figure 4D Table 2 ) tested by qRT-PCR in Ezh2 control and mutant GC B cells described in C. The genes were grouped based on whether expression was upregulated (up) or remained unchanged (no change) in Ezh2 mutant GC B cells. ***P = 0.0009 (Fisher's exact test).
D and E, and Supplemental Figure 4 , E and F). Importantly, AID inactivation led to the normalization of apoptosis of Ezh2 mutant GC B cells (Figure 4 , F and G), allowing for the first time efficient recovery of cells that had recombined both Ezh2 fl alleles ( Figure  4H ). These results show that EZH2 protects against DNA damage-induced apoptosis, in particular, in GC B cells, genotoxicity linked to AID mutagenesis.
Ezh2 regulates the GC B cell transcriptional program. Despite the consistent normalization of apoptosis, Ezh2 fl/fl :Aicda -/-:Cr2-cre compound mutants showed still a modest, yet reproducible, reduction in GC B cell numbers and, in few cases, Ezh2/Aicda double-mutant GC B cells remained counter selected (Supplemental Figure 4G) . These results suggested additional function(s) of Ezh2 in GC B cells. To address this, we performed H3K27me3 ChIP assays coupled to high-throughput sequencing (ChIP-seq) to identify Ezh2 target genes in GC B cells at a genome-wide level. We used the modelbased analysis of ChIP-seq peak calling software and applied a stringent P value (P < 10 10 -10 ) cutoff for peak detection that we recently validated to uncover the core subset of polycomb targets in somatic cell reprogramming (21) . A similar approach was used for global identification of targets of H3K4me3 that marks actively transcribed loci. In GC B cells, we identified 7,404 genes that carried H3K27me3 in a 10-Kb genomic interval centered on the TSS. Of these targets, 41% (3,082 out of 7,404 genes) carried the H3K4me3 mark also, thus representing bivalent genes ( Figure  5A and Supplemental Table 1 ). Instead, 7,436 genes were exclusively marked by H3K4me3 ( Figure 5A and Supplemental Table 1 ).
To gain insights into the biological function of H3K27me3 targets in GC B cells, we performed a Gene Ontology analysis. Genes marked by H3K27me3 were significantly (P ≤ 0.01) enriched for categories involved in developmental processes (Supplemental Figure 5A ), whereas H3K4me3 preferentially marked genes involved in metabolism (Supplemental Figure 5B) . To understand the influence of H3K27me3 on target gene expression, we compared the average transcript levels of genes marked in GC B cells, by H3K27me3, H3K4me3, or by both, respectively. In accordance with previous observations (22), we found that genes marked by H3K27me3 were significantly (P < 2.2 10 -16 ) less transcribed than those marked by H3K4me3 ( Figure 5B ). Transcripts encoded by bivalent genes showed intermediate levels, which were significantly lower (P < 2.2 10 -16 ) than those derived from H3K4me3-marked genes ( Figure 5B ). These data pointed to a role for EZH2 in transcriptional silencing of target genes in GC B cells. To test this, we quantified the transcript levels of a representative set of genes in Ezh2 mutant and control GC B cells (n = 67) selected according to H3K27me3 status and relevance in B cell biology (Supplemental Table 2 ). We found that differentially expressed genes (P < 0.05) were all upregulated in Ezh2 mutant GC B cells ( Figure 5C ) and preferentially marked by H3K27me3 in Ezh2-proficient GC B cells ( Figure  5D and Supplemental Figure 5C ). These included key regulators of cell cycle progression (Cdkn1a, Cdkn1b, and Cdkn2a) and GC B cell differentiation (Id2, Blimp1, Irf4, and Xbp1; Figure 5C ). For IRF4, we confirmed the upregulation at the protein level. Moreover, the fraction of cells expressing high IRF4 levels increased significantly in GCs of Ezh2 conditional mutants (Supplemental Figure 6, A  and B) . Instead, the expression of H3K4me3-only targets remained largely unaffected in response to Ezh2 inactivation (data not shown). Collectively, these data assign a critical control over cell cycle progression and differentiation of GC B cells to EZH2.
Ezh2 facilitates B cell proliferation independent of repression of CDK inhibitors. The identification of Cdkn1a, Cdkn1b, Cdkn2a as targets of H3K27me3 in GC B cells pointed to a role for EZH2 in the regulation of cell cycle progression, possibly through the repression of CDK inhibitors (8, 23) . To test this hypothesis, given the difficulty in tracking the few Ezh2 mutant GC B cells in vivo, we performed cell cycle distribution analysis after in vitro activation of Ezh2 mutant B cells with membrane-bound CD40L and IL-4. Acute EZH2 inactivation in B cells led to an accumulation of cells in the G 0 /G 1 phase of the cell cycle ( Figure 6, A and B) . Expression analysis revealed a substantial upregulation of the CDK inhibitor p16 Ink4a in Ezh2 mutant B cells ( Figure 6C ). To determine whether induction of p16 Ink4a was responsible for the defect in G 1 -to-S transition of Ezh2 mutant B cells, we analyzed the cell cycle profile of Ezh2/Cdkn2a double-mutant B cells after CD40L/IL-4 stimulation. In contrast to previous results (24, 25) , Cdkn2a inactivation failed to normalize the cell cycle profile of Ezh2 mutant B cells ( Figure 6D) . Moreover, expression of other CDK inhibitors was largely unaffected in Ezh2 mutant primary B cells after mitogenic stimulation, excluding their possible involvement in the cell cycle defect ( Figure 6C ). All together these results unravel a novel mechanism that uncouples EZH2 control of G 1 -to-S transition from the repression of CDK inhibitors.
Ezh2 is required for repression of a subset of BCL6 targets in GC B cells.
We noticed that several genes upregulated in Ezh2 mutant GC B cells are bound with high significance and repressed by the transcriptional repressor BCL6 in GC B cells (26) . Given the relevance of BCL6 in the regulation of the GC reaction (27), we investigated the influence of EZH2 on BCL6-dependent gene silencing. Specifically, we quantified the transcript levels of 49 highly significant (false discovery rate [FDR] ≤ 0.0001) BCL6 targets in Ezh2 mutant GC B cells (27) . Of these, around one-third (n = 16) were marked by H3K27me3 in wild-type GC B cells (Supplemental Table 3 ). Whereas expression of BCL6 targets lacking H3K27me3 remained largely unaltered by Ezh2 inactivation (3 out of 33 genes), nearly half of the genes bound by PRC2 and BCL6 in wild-type GC B cells (7 out of 16 genes; Bcl2, Id2, Cdkn1b, Cdkn2a, Myb, Blimp1, and Irf4) were upregulated in the Ezh2 mutant counterparts (Figure 5C , Figure 7A , and Supplemental Table 3 ). To exclude that EZH2 regulated the BCL6 gene, we crossed conditional Ezh2 mutant mice (Ezh2 fl/fl :C 1-cre mice) with I HABCL6 knockin ani- mals expressing BCL6 under the I promoter that is constitutively active in B cells (28) . Expression analysis performed on primary GC B cells of compound mutants revealed the failure of I HABCL6 to normalize expression of a subset of H3K27me3/BCL6 shared targets ( Figure 7B ). These results indicate that EZH2 regulates BCL6 repressor function on a subset of common targets in GC B cells.
H3K27me3 marking of Blimp1 and Irf4 in GC B cells is erased upon induction of PC differentiation.
Bioinformatic analysis of ChIPseq data identified the PC determinant Blimp1 as a target of H3K27me3 in mouse GC B cells, in accordance with recent findings in the human counterparts (23) . We confirmed this result by performing H3K27me3 ChIP-qPCR analyses on primary GC B cells ( Figure 8A ) and A20 and I.29 + murine B lymphoma cells (Supplemental Figure 7A ) expressing low levels of Blimp1 (Supplemental Figure 7F ). Accordingly, the PRC2 core component Suz12 was recruited to the Blimp1 locus in BLIMP-negative B cells (Supplemental Figure 7B) . In a similar fashion, screening by ChIPqPCR identified H3K27me3 deposition in a region proximal to the Irf4 TSS in primary GC B cells and A20 and I.29 + lymphoma cells ( Figure 8A and Supplemental Figure 7A ). These results establish that Blimp1 and Irf4 are direct targets of PRC2 in GC B cells.
To study the regulation of H3K27 trimethylation at the Blimp1 and Irf4 loci during terminal differentiation, we stimulated B cells in vitro with either LPS or IL-21. A substantial loss of H3K27me3 at the Blimp1 and Irf4 loci ( Figure 8B ) was detected within the first 24-48 hours after stimulation. In particular, for Irf4, this coincided with loss of Suz12 binding, increased H3K4 trimethylation, and recruitment of RNA polymerase II to the promoter, which correlated (29) . Efficient Ezh2 inactivation in iGB cells led to a substantial reduction in global H3K27me3 levels ( Figure 8C ) that was confirmed at the Blimp1 and Irf4 loci by ChIP-qPCR analysis ( Figure 8D ). Ezh2 mutant iGB cells expressed higher Irf4 and Blimp1 transcript levels ( Figure 8E ), which was alone sufficient to trigger differentiation of a subset of CD40-activated B cells into Irf4 hi CD138 + PCs (Supplemental Figure 8A) . Importantly, upon IL-21 stimulation, over one-third of Ezh2 mutant iGB cells differentiated into Irf4 hi CD138 + PCs, significantly outnumbering those present in control cultures (Figure 8, F and G) . In accordance with this result, conditioned media of Ezh2 mutant iGB cultures stimulated with IL-21 contained higher levels of soluble IgG1 antibodies ( Figure 8H ), which coincided with a greater number of IgG1 + antibody-secreting cells, when compared with controls (Supplemental Figure 8B ). These results indicate that EZH2 repression of Blimp1 and Irf4 restricts IL-21-controlled PC differentiation.
Y641 mutant of EZH2 enforces BLIMP1 repression to support DLBCL growth. BLIMP1 has been proposed tumor suppressor since its inactivation occurs frequently in human DLBCL and promotes B cell lymphomas in mouse models (30) (31) (32) . In DLBCL, impaired BLIMP1 expression results from genetic alterations of the BLIMP1 locus or stable repression by BCL6 (32) . BLIMP1 mutations have been almost exclusively associated with ABC-type DLBCL (30, 32) . Since EZH2 gain-of-function mutations occur predominantly in GC-type DLBCL (9) and given that Blimp1 is a direct target of EZH2 repression in primary mouse GC B cells, we investigated whether EZH2 was required for stable BLIMP1 silencing in GC-type DLBCL. To this aim, we treated the DLBCL cells lines, SU-DHL-4 and SU-DHL-6, expressing constitutively active forms of EZH2 (9, 33) with the EZH2 small molecule inhibitor, GSK343 (34) . Treatment of tumor cells with 2.5 M GSK343 led to a reduction in global levels of H3K27me3, without interfering with EZH2 expression (Supplemental Figure 9,  A and B) . Importantly, exposure of DLBCL cells to GSK343 induced a substantial upregulation of BLIMP1 expression in both DLBCL lines ( Figure 9A ). This effect was associated with impaired in vitro lymphoma growth ( Figure 9B ) that was contributed by a partial arrest in cell cycle progression at the G 1 -to-S regulation of the GC B cell transcriptional program. H3K27me3 targets were preferentially repressed in GC B cells and strongly enriched for developmental regulators, supporting the notion that, in differentiated cells, PRC2 has a critical function to preserve silencing of transcriptional programs driving alternative cell fates. Importantly, EZH2 also exerted a direct control of the expression of a substantial number of genes that regulate the persistence and expansion of B cells within the GC reaction. EZH2 was required to repress Id2, the inhibitor of the E-box protein E2A, whose function is necessary for GC B cells (42) . In GC B cells, EZH2 was also critical to prevent the expression of the cyclin-dependent kinase inhibitor p16 INK4A encoded by the Cdkn2a locus, which regulates G 1 -to-S transition. In accordance with this, a higher proportion of Ezh2 mutant cells was arrested at the G 0 /G 1 stage after CD40 stimulation. Surprisingly, in contrast to previous reports, the cell cycle defect was neither rescued by Cdkn2a inactivation nor associated with substantial changes in the expression of other CDK inhibitors. These results unravel a novel mechanism through which EZH2 facilitates G 1 -to-S progression that is independent of CDK repression.
Of note, the majority of H3K27me3 targets that we found upregulated in Ezh2 mutant GC B cells are bound and repressed by BCL6 (26) , which is essential for GC B cell function (27) . This result underscores a possible cooperation between PRC2 and BCL6 in the repression of common targets, which include important negative regulators of GC B cell function, such as Id2 and Blimp1. Our data support a scenario in which EZH2 primarily regulates BCL6 repressor activity, as enforced BCL6 expression was not sufficient in Ezh2 mutant GC B cells to restore repression of a representative subset of shared targets.
One of the main findings of this study is the identification of PC determinants Blimp1 and Irf4 (43) (44) (45) as direct targets of EZH2 repression in GC B cells. Blimp1 and Irf4 genes were marked by H3K27me3 and bound by PRC2 in B cells prior to onset of PC differentiation. This regulation was critical to repress Blimp1 and Irf4, since transcripts for both PC determinants were significantly upregulated in Ezh2 mutant GC B cells. The induction of the PC program in GC B cells following EZH2 inhibition was completed by the upregulation of Xbp1, which is required to sustain high rates of Ig synthesis (46, 47) . Acute Ezh2 inactivation was sufficient to trigger terminal differentiation of a subset of CD40-activated B cells. More strikingly, the addition of IL-21 substantial boosted differentiation of PcG mutant B cells into antibody-secreting cells in response to CD40 stimulation. This result indicates that EZH2 limits the amplitude of the PC response induced by IL-21 (48), thereby possibly extending the persistence of B cells in the GC (49, 50) . We propose that, in GC B cells, EZH2 modulates IL-21-dependent Blimp1 expression via H3K27 trimethylation (51, 52) . Therefore, signals regulating PRC2 recruitment at the Blimp1 locus are predicted to influence the balance between IL-21-dependent Bcl6 and Blimp1 expression and, thereby, the decision of B cells to persist rather than exit from the GC reaction. The control of Irf4 expression exerted through H3K27me3 is likely to contribute to the regulation by EZH2 of the fate of GC B cells (53) .
The increased susceptibility of Ezh2 mutant B cells to PC differentiation is seemingly in contrast with reduced serum Ig titers measured in PcG mutant animals after immunization with T celldependent antigens. The increased apoptosis may represent a major obstacle for Ezh2 mutant B cells to exit the GC as antibodysecreting cells. Moreover, whereas EZH2 inactivation interferes transition (Supplemental Figure 9C) . To understand whether Y641 mutant of EZH2 exerted its catalytic activity within PRC2, we inhibited the expression of the essential PRC2 subunit EED in DLBCL cells. Downregulation of EED in SU-DHL-4 cells (Supplemental Figure 9 , D and E) caused a global reduction in H3K27me3 levels (Supplemental Figure 9F) and, most importantly, a substantial upregulation of BLIMP1 expression ( Figure 9C ). Similar results were obtained in A20 lymphoma B cells expressing wild-type EZH2 (Supplemental Figure 10) . Inhibition of EED interfered with in vitro DLBCL growth ( Figure  9D ) and impaired cell cycle progression (Supplemental Figure  9G ), extending our data as well as that of others based on the use of EZH2 small molecule inhibitors (23, (35) (36) (37) . In a subset of SU-DHL-4 cells, PRC2 inhibition alone was sufficient to cause the induction of surface CD138 expression and the downregulation of MHC class II molecules, which accompanies terminal differentiation (Supplemental Figure 9H) . To test whether induction of BLIMP1 was alone sufficient to influence growth of B lymphoma cells expressing a constitutively active form of EZH2, we complemented WSU-DLCL-2 DLBCL cells with a BLIMP1 expression vector. Transient expression of BLIMP1 ( Figure 9E ) caused a severe impairment in in vitro growth of DLBCL, which ultimately led to fewer lymphoma cells retrieved 2 days after complementation ( Figure 9F ). All together, these results indicate that constitutively active EZH2 represses the tumor suppressor BLIMP1 via PRC2 to facilitate the growth of GC-type DLBCL.
Discussion
The strong induction of EZH2 in GC B cells, combined with the frequent occurrence of EZH2 gain-of function mutations in GCderived NHL, suggested a role for the PcG protein in the regulation of the GC reaction. Indeed, using cell type-specific gene targeting in mice, we show that Ezh2 methyltransferase activity is strictly required for GC B cell function. EZH2 inactivation resulted in fewer GCs, reduced numbers of high-affinity long-lived memory B cells, and impaired production of antigen-specific antibodies upon encounter with T cell-dependent antigens.
The failure to sustain the GC reaction was largely contributed by enhanced apoptosis of Ezh2 mutant B cells, which was independent of p19 ARF upregulation and resistant to constitutive BCL2 expression. Strikingly, instead, GC B cells lacking functional EZH2 became highly vulnerable to genotoxic stress associated with AID function. As a consequence of premature death, Ezh2 mutant GC B cells carried fewer Ig V gene mutations and failed to be selected by antigen-driven selection. The enrichment for apoptotic cells among Ig class-switched Ezh2 mutant B cells suggests a possible contribution of the PcG protein to the repair of DNA breaks generated during IgH isotype switching, extending previous findings (16, 18, 19, 38) . In support of this, Ezh2 mutant primary B cells displayed higher numbers of DNA damage foci marked by 53BP1 after exposure to a sublethal dose of IR. The failure of Ezh2 mutant GC B cells to preserve genome integrity may trigger ultimately their death, possibly as a consequence of mitotic catastrophe. This scenario does not exclude that EZH2 may act to limit the genomewide recruitment of AID via H3K27me3-dependent silencing of target genes (39, 40) . Future studies will establish whether EZH2 inactivation increases the frequency of off-target mutations caused by AID, in particular at bivalent genes (40, 41) .
Global identification of H3K27me3 targets combined with expression analyses revealed a critical contribution of EZH2 to the (C36B11; Cell Signaling), or EZH2-specific (AE25.13; K. Helin, University of Copenhagen, Copenhagen, Denmark) mAb conjugated in house with Alexa Fluor dyes according to manufacturer's instructions (Molecular Probes, Invitrogen). Samples were acquired on a FACSCalibur (BD Biosciences), and data were analyzed with FlowJo software (Tree Star).
Immunoblotting analysis. Immunoblotting analyses were performed with antibodies specific for EZH2 (AE25-13; K. Helin), H3K27me3 (07-449; Upstate), histone H3 (07-690; Millipore), and EED (AA19-30; K. Helin), respectively. Immunoblot images were acquired using the ChemiDoc system (Bio-Rad).
Analysis of apoptosis and DNA damage. GC B cell apoptosis was measured with the CaspGLOW Staining Kit (BioVision). Irradiation was performed using a Faxitron (X-Ray Corporation) on MACS-purified primary B cells stimulated in vitro for 48 hours with 20 g/ml LPS. TUNEL staining was performed using the In situ Cell Death Detection Kit (Roche) following the manufacturer's instructions. Cells were acquired on a FACSCalibur (BD Biosciences), and data were analyzed with FlowJo software (Tree Star). 53BP1 + DNA damage foci were quantified in LPS-activated primary B cells 2.5 hours after exposure to 0.2 Gy of IR. To detect 53BP1 + foci, cells were fixed in PBS/4% paraformaldehyde, permeabilized, and stained with 53BP1-specific antibody (Novus Biologicals, NB100-304), and foci were visualized with a fluorescent-labeled secondary antibody in combination with DAPI staining. Photographs were acquired using an upright fluorescence microscope (Olympus AX-70; 40 magnification). Cells with 2 or more 53BP1 + foci were counted.
Cell cycle analysis. iGB cells were pulsed with EdU (44 M; Invitrogen) for 1 hour followed by EdU measurement using the Click-iTEdU Alexa Fluor 647 Flow Cytometry Assay kit according to the manufacturer's instructions (Invitrogen). DLBCL were labeled with BrdU (33 M; Sigma-Aldrich) for 1 hour followed by determination of BrdU according to manufacturer's instructions (BD Pharmingen). Samples were stained with propidium iodide, acquired on a FACSCalibur (BD Biosciences), and analyzed using FlowJo software (Tree Star).
ELISA. To quantify NP-specific serum antibodies, plates were coated with 2 g/ml NP23-BSA or NP4-BSA, respectively (Biosearch Technologies), and bound were antibodies detected with biotin-conjugated antiIgM (R33.24.12) or anti-IgG1 (550331; BD Pharmingen) antibodies. IgG1 levels in conditioned media of iGB cultures were measured using a combination of rat anti-mouse IgG1 antibodies (MCA1289 [ABD Serotec] and A85-1 [BD Pharmingen]).
ELISPOT. MultiScreen HTS-HA filter plates (MSHAS4510; Millipore) were coated with 1 g rat anti-mouse IgG1 (LO.MG1-13; ABD Serotec). Cells were seeded for 6 hours at 37°C, and bound IgG1 antibodies were detected with biotinylated rat anti-mouse IgG1 (A85-1; BD Pharmingen) followed by streptavidin coupled to alkaline phosphatase (ELIspot Kit; R&D Systems). Images of plates were acquired, and the number of spots was scored using ImageJ software.
qPCR analysis. qRT-PCR was performed in triplicate with SYBR Green-I Master Mix using primer combinations listed in Supplemental Table 4 or using custom-made TaqMan Array Micro Fluidic Cards (Applied Biosystems). Probe sets are listed in Supplemental Table 4 . Expression values were calculated as 2 -ct . Ezh2 gene copy number was quantified by qPCR using primers annealing to genomic DNA lying within the loxP-flanked segment (Supplemental Table 4 ). Values were calculated using the comparative CT method. To normalize for DNA input, a segment of the Gapdh gene was amplified using primers listed in Supplemental Table 4 .
Ig VH gene mutation analysis. Ig rearrangements bearing the VH186.2 gene were analyzed as described previously (61) . PCR primers are listed in Supplemental Table 4 .
Histology. Snap-frozen spleens were embedded in Cryo-M-Bed (Bright Instruments). Sections mounted onto multispot glass slides (Hendley) neither with Blimp1-controlled Xbp1 expression nor with the establishment of the transcriptional program that supports the unfolded protein response (short-lived Ezh2 mutant PCs secrete normal amounts of antibodies in vitro), additional experiments will be required to determine whether EZH2 is required for longterm PC persistence (54) .
The identification of Blimp1 as a direct target of EZH2 is relevant for the understanding of the mechanisms through which the PcG protein may contribute to the pathogenesis of DLBCL. BLIMP1 loss-of-function mutations occur frequently in ABC-type DLBCL and accelerate lymphomagenesis in mouse models, supporting its role as tumor suppressor (30) (31) (32) . The rare occurrence of BLIMP1 mutations in GC-type DLBCL suggests the existence of additional mechanisms that could prevent its expression in this form of NHL. Using pharmacological inhibition of EZH2 and functional inactivation of PRC2, we provide evidence that constitutively active EZH2 enforces BLIMP1 silencing in GC-type DLBCL cells. While our manuscript was under review an independent study reached similar conclusions (23) . Importantly, we provide evidence that BLIMP1 induction alone is sufficient to impair in vitro growth of GC-type DLBCL expressing mutant EZH2. Thus, epigenetic silencing of BLIMP1 may represent an important mechanism through which EZH2 supports lymphoma growth.
In conclusion, our data indicate that EZH2 methyltransferase activity is strictly required for the establishment of a protective long-term B cell adaptive immune response. EZH2 accomplishes this function through the coordinated regulation of GC B cell differentiation, proliferation, and response to genotoxic damage imposed by AID. Conversely, enforced BLIMP1 repression, coupled to protection against AID mutagenesis, acceleration of S-phase entry, and support for BCL6 function, may represent the mechanism through which constitutively active EZH2 contributes to lymphomagenesis. These results provide a rationale for use of EZH2 inhibitors (35) (36) (37) in combination with inducers of terminal differentiation, such as IL-21 (55, 56) and genotoxic agents, in the treatment of GC-derived DLBCL and follicular lymphoma.
Methods
Mice. Ezh2 fl , R26-yfp, Cr2-cre, C 1-cre, Cdkn2a -/-, E -BCL2, Aicda -/-, and I HABCL6 mice were previously described (11-13, 28, 57-60) . Compound mutants were backcrossed to C57BL/6J mice for 6 or more generations and kept under specific pathogen-free conditions. Eight-to sixteen-week-old mice were immunized by intraperitoneal injection of alum-precipitated NP-CGG25-36 (100 g per mouse; Biosearch Technologies) or NP-CGG25/PBS (50 g per mouse) for secondary responses. Sheep red blood cells (1 10 8 cells per mouse; Oxoid) were resuspended in PBS and injected intraperitoneally.
Antibodies. Flow cytometry was performed using fluorescent-or biotinlabeled antibodies reactive to mouse CD19 (1D3; eBioscience), CD21 (8D9; eBioscience), CD23 (B3B4; eBioscience), CD38 (90; eBioscience), IgD (11.26; eBioscience), CD184 (2B11; eBioscience), CD95 (Jo2; BD Biosciences), CD138 (281-2; BD Biosciences), IgG1 (A85-1; BD Biosciences), IgM (R33.24.12; K. Rajewsky, Max Delbrück Center for Molecular Medicine, Berlin, Germany), CD45R/B220 (RA3-6B2; K. Rajewsky), and Ig (R33-18-10; K. Rajewsky). Antibodies against human MHC class II and CD138 were provided by S. Cenci (San Raffaele Scientific Institute). NP binding was assessed using NIP-BSA conjugated to allophycocyanin (provided by M. Hikida, Kyoto University, Kyoto, Japan and T. Takemori, RIKEN, Yokohama, Japan). PNA was from Vector Laboratories. For intracellular stainings, B cells where fixed, permeabilized in Cytofix/Cytoperm (BD Biosciences), and stained with IRF4-specific (3E4; BioLegend), H3K27me3-specific
